De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Dimerix Beheer

Beheer criteriumcontroles 2/4

De CEO Dimerix's is Nina Webster, benoemd in Aug2018, heeft een ambtstermijn van 6.17 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 759.06K, bestaande uit 49.1% salaris en 50.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.073% van de aandelen van het bedrijf, ter waarde A$ 149.37K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 7 jaar.

Belangrijke informatie

Nina Webster

Algemeen directeur

AU$759.1k

Totale compensatie

Percentage CEO-salaris	49.1%
Dienstverband CEO	6.2yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01

Analyse CEO-vergoeding

Hoe is Nina Webster's beloning veranderd ten opzichte van Dimerix's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$759k	AU$373k	-AU$17m
Mar 31 2024	n/a	n/a	-AU$14m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$387k	AU$350k	-AU$14m
Mar 31 2023	n/a	n/a	-AU$14m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$12m
Jun 30 2022	AU$517k	AU$341k	-AU$10m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$408k	AU$334k	-AU$6m
Mar 31 2021	n/a	n/a	-AU$6m
Dec 31 2020	n/a	n/a	-AU$6m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$539k	AU$304k	-AU$4m
Mar 31 2020	n/a	n/a	-AU$4m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$4m
Jun 30 2019	AU$486k	AU$221k	-AU$3m

Compensatie versus markt: De totale vergoeding ($USD 523.85K ) Nina } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 313.13K ).

Compensatie versus inkomsten: De vergoeding van Nina is gestegen terwijl het bedrijf verliesgevend is.

CEO

Nina Webster

6.2yrs

Tenure

AU$759,063

Compensatie

Dr. Nina Webster, Ph D., BSc (Hons), M IP Law, MBA, has been Chief Executive Offer, Managing Director and Director of Dimerix Limited since August 27, 2018. Dr. Webster served as the Commercial Director of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nina Webster	CEO, MD & Director	6.2yrs	AU$759.06k	0.073% A$ 155.5k
David Fuller	Chief Medical Officer	less than a year	AU$361.30k	0.0033% A$ 7.0k
Robert Shepherd	Chief Commercialisation Officer	less than a year	AU$372.79k	geen gegevens
Hamish George	CFO & Company Secretary	5.8yrs	geen gegevens	geen gegevens
Kevin Pfleger	Chief Scientific Advisor	no data	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van DXB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nina Webster	CEO, MD & Director	6.2yrs	AU$759.06k	0.073% A$ 155.5k
Mark Diamond	Non-Executive Chairman	less than a year	AU$52.50k	geen gegevens
Hugh Alsop	Independent Non-Executive Director	7.4yrs	AU$60.00k	geen gegevens
Sonia Poli	Non Executive Director	9.3yrs	AU$60.00k	0.10% A$ 212.7k
Alessia Fornoni	Member of Medical Advisory Board	7yrs	geen gegevens	geen gegevens
David Power	Member of Medical Advisory Board	7yrs	geen gegevens	geen gegevens
Daniel Cattran	Member of Medical Advisory Board	7yrs	geen gegevens	geen gegevens
Jonathan Hogan	Member of Medical Advisory Board	7yrs	geen gegevens	geen gegevens
Clinton Snow	Non-Executive Director	1.4yrs	AU$60.00k	geen gegevens

7.0yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van DXB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Dimerix Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Dimerix Limited, Annual General Meeting, Oct 01, 2024

Non Executive Director exercised options to buy AU$70k worth of stock.

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

Dimerix Limited, Annual General Meeting, Nov 21, 2023

Less than half of directors are independent

Recent updates

Dimerix Limited, Annual General Meeting, Oct 01, 2024

Non Executive Director exercised options to buy AU$70k worth of stock.

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

New major risk - Share price stability

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.20

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.46

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur